Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
复制标题
DOI：
10.1371/journal.pone.0134324
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Hoffman RM
中科院分区：
文献类型：
--
作者：
Hiroshima Y;Zhao M;Zhang Y;Zhang N;Maawy A;Murakami T;Mii S;Uehara F;Yamamoto M;Miwa S;Yano S;Momiyama M;Mori R;Matsuyama R;Chishima T;Tanaka K;Ichikawa Y;Bouvet M;Endo I;Hoffman RM
建立人源软组织肉瘤裸鼠模型，分为以下几组：(1)对照组；(2)吉西他滨(GEM)(80 mg/kg，ip，每周3周)；(3)帕唑帕尼(100 mg/kg，口服，每日3周)；(4)鼠伤寒沙门氏菌A1-R(5×107CFU/体，ip，每周3周)。肉瘤对GEM耐药(p=0.879)。与未经治疗的小鼠相比，帕佐帕尼有缩小肿瘤体积的趋势，但没有显著差异(p=0.115)。与未经治疗的小鼠相比，鼠伤寒沙门氏菌A1-R显著抑制肿瘤生长(p=0.001)。在所有治疗方法中，鼠伤寒沙门氏菌A1-R是唯一有效的治疗软组织肉瘤裸鼠模型的方法，包括新批准的多重酪氨酸激酶抑制剂帕唑帕尼。这些结果表明，肿瘤靶向鼠伤寒沙门氏菌A1-R是一种有希望的治疗耐药软组织肉瘤的方法。
A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemo-resistant soft-tissue sarcoma.